Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited reports developments around its consumer health sciences business, led by IM8, a premium health and longevity brand focused on daily nutrition and supplementation. Company updates commonly cover IM8 product lines such as Daily Ultimate Essentials, Daily Ultimate Longevity and The Beckham Stack, as well as brand partnerships across professional sports, preventive health testing and nutrition-access initiatives.
Recurring Prenetics news also includes financial results, earnings calls, revenue and profitability commentary, share repurchase activity, executive share purchases, balance-sheet positioning and capital allocation. Recent corporate updates reflect the company’s strategic focus on IM8 following divestitures and a shift away from digital-asset treasury expansion.
Prenetics (NASDAQ: PRE) will attend the 38th Annual ROTH Conference in Laguna Niguel, CA, March 22–24, 2026. Management will hold one-on-one investor meetings and participate in a fireside chat at 8:30 a.m. PT and a Consumer Influencer panel at 12:00 p.m. PT on Monday, March 23, 2026. Both sessions will be available via webcast on the company’s investor relations website. To schedule meetings, investors should contact Investor Relations or their ROTH representative.
Prenetics (NASDAQ: PRE) authorized a $40.0 million share repurchase program over 12 months, bringing total insider and board-backed commitment to $42.75 million. The company reports $164 million in total adjusted liquidity, zero debt, and IM8 guidance of $180–200 million revenue for 2026, targeting adjusted EBITDA profitability by Q4 2027. Management purchased ~$2.75 million of stock in recent post-earnings windows. The program allows open market, negotiated and Rule 10b5-1 purchases and may be modified or suspended at any time.
Prenetics (NASDAQ: PRE) executives executed a second consecutive round of post-earnings open market purchases during Feb 23–27, 2026. The leadership team bought 76,060 shares for approximately $1.301 million at an average price of ~$17.11 per share.
Combined with prior purchases in November 2025, executives have personally invested about $2.75 million across two post-earnings windows. CEO Danny Yeung purchased 42,282 shares for ~$750,000 (~$17.71/share) in this round; other officers also made purchases. Management said the IM8 business is performing and the share price does not yet reflect that progress.
Prenetics (NASDAQ: PRE) launched IM8 Daily Ultimate Essentials PRO on February 23, 2026 — a clinical‑grade reformulation with up to 733% greater potency across 11 nutrients, new saffron nootropic, and bioactive vitamin upgrades.
The PRO formula adds two flavours (Mango + Passionfruit; Lemon + Orange), keeps the same price for new and existing customers, and auto‑upgrades subscribers at their next delivery. Product claims include >10,000 five‑star reviews, >670,000 purchases, and >20 million servings. Full supplement facts available at the product page.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million in escrow.
As of Feb 15, 2026, total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; alternative assets $35.2M). The company reports zero outstanding debt and will report Q4 and full-year 2025 results pre-market on Feb 18, 2026.
Prenetics (NASDAQ: PRE) reported record FY2025 results: total revenue $92.4M (up ~480% YoY) and Q4 revenue of $36.6M (+55% QoQ). IM8 reached $10.0M monthly revenue in Dec 2025 and $120M ARR within 12 months, contributing $60.1M in FY2025.
Strategic divestitures (ACT Genomics, Europa, Insighta) boosted total adjusted liquidity to $171.1M as of Feb 15, 2026, with zero debt. Company reiterated 2026 IM8 revenue guidance of $180–$200M.
Prenetics (NASDAQ: PRE) appointed Dr. Darshan Shah to its Board of Directors, effective February 16, 2026. Dr. Shah joins the Audit, Compensation, and Nominating and Corporate Governance Committees and brings clinical longevity expertise, Mayo Clinic surgical training, and consumer product formulation experience highlighted by a Super Bowl Feb 6, 2026 appearance.
He founded Next Health, which plans >30 locations by end of 2026, and will support Prenetics’ IM8 clinical trials and product development efforts.
Prenetics (NASDAQ: PRE) completed the sale of its 35% equity interest in Insighta to Tencent for $70.0 million, receiving $69.0 million on Feb 13, 2026 with $1.0 million held in escrow.
As of Feb 15, 2026 total adjusted liquidity is $171.1 million (cash $99.3M; financial assets $29.3M; ACT escrow $6.3M; Bitcoin $35.2M). Prenetics reports zero outstanding debt and says proceeds will fund IM8 global expansion, innovation and clinical programs.
Prenetics (NASDAQ: PRE) named Formula 1 driver Ollie Bearman as Global Ambassador and shareholder on Feb 13, 2026. IM8, co-founded by David Beckham, achieved US$100 million ARR in 11 months and cites NSF Certified for Sport® designation for its Daily Ultimate Essentials.
The partnership follows Bearman’s reported use of IM8 products and aligns the brand with elite athletes and a noted Scientific Advisory Board.
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
The company will host an earnings conference call the same day at 10:00 a.m. Eastern Time with a Q&A session; an audio replay will be available on the investor relations website.